Determinants of early Elexacaftor-Tezacaftor-Ivacaftor use in adults with cystic fibrosis and preserved lung function: insights from a European multicenter survey - PubMed
5 hours ago
- #Cystic Fibrosis
- #Preserved Lung Function
- #ETI Treatment
- Survey conducted among 25 European adult CF centers to explore factors influencing ETI (Elexacaftor-Tezacaftor-Ivacaftor) initiation in adults with cystic fibrosis and preserved lung function (ppFEV₁ >90%).
- Most specialists (69.6%) favored early ETI treatment initiation in all eligible patients.
- Key factors influencing ETI initiation included respiratory symptoms, microbiological and imaging features, patient willingness, age over 50, history of mental health issues, and pregnancy desire.
- Variability in prescribing practices highlights the need for longitudinal studies to clarify long-term outcomes of ETI in this population.